Coloplast 관리

관리 기준 확인 4/4

Coloplast CEO는 Kristian Villumsen, Dec2018 에 임명되었습니다 의 임기는 4.42 년입니다. 총 연간 보상은 DKK 21.40M, 54.2% 로 구성됩니다. 54.2% 급여 및 45.8% 보너스(회사 주식 및 옵션 포함). 는 MX$ 213.31M 가치에 해당하는 회사 주식의 0.043% 직접 소유합니다. 213.31M. 경영진과 이사회의 평균 재임 기간은 각각 5.1 년과 5.3 년입니다.

주요 정보

Kristian Villumsen

최고 경영자

DKK 21.4m

총 보상

CEO 급여 비율	54.2%
CEO 임기	4.4yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	5.1yrs
이사회 평균 재임 기간	5.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Kristian Villumsen 의 보수는 Coloplast 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	n/a	n/a	DKK 5b
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b
Jun 30 2018	n/a	n/a	DKK 4b
Mar 31 2018	n/a	n/a	DKK 4b
Dec 31 2017	n/a	n/a	DKK 4b
Sep 30 2017	DKK 10m	DKK 6m	DKK 4b
Jun 30 2017	n/a	n/a	DKK 3b
Mar 31 2017	n/a	n/a	DKK 3b
Dec 31 2016	n/a	n/a	DKK 3b
Sep 30 2016	DKK 10m	DKK 6m	DKK 3b

보상 대 시장: Kristian 의 총 보상 ($USD 3.11M ) MX 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 5.78M ).

보상과 수익: Kristian 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Kristian Villumsen (52 yo)

4.4yrs

테뉴어

DKK 21,400,000

보상

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kristian Villumsen	President & CEO	4.4yrs	DKK 21.40m	0.043% MX$ 213.3m
Anders Lonning-Skovgaard	Executive VP & CFO	8.8yrs	DKK 10.80m	데이터 없음
Allan Rasmussen	Executive Vice President of Global Operations	8.8yrs	DKK 9.60m	0.00015% MX$ 749.3k
Nicolai Andersen	Executive Vice President of Innovation	no data	DKK 9.00m	데이터 없음
Paul Marcun	Executive Vice President of Growth	4.3yrs	DKK 11.00m	데이터 없음
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000030% MX$ 149.9k
Ellen Bjurgert	Vice President of Investor Relations	6.6yrs	데이터 없음	데이터 없음
Dennis Kaysen	Director of Corporate Communications	no data	데이터 없음	데이터 없음
Dorthe Ronnau	Senior Vice President of People & Culture	1.3yrs	데이터 없음	데이터 없음
Alain Morvan	Senior Vice President of Sales Europe	11.1yrs	데이터 없음	데이터 없음
Rasmus Møller	Senior Vice President of Wound & Skin Care	2.7yrs	데이터 없음	데이터 없음
Manu Varma	Senior Vice President of Chronic Care - North America	5.1yrs	데이터 없음	데이터 없음

5.1yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: 0QBO N 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Barfod	Senior Controller & Employees Representative Director	17.3yrs	DKK 450.00k	0.000030% MX$ 149.9k
Carsten Hellmann	Independent Director	5.4yrs	DKK 690.00k	0.0028% MX$ 14.1m
Lars Rasmussen	Chairman of the Board	4.4yrs	DKK 1.84m	0.098% MX$ 487.8m
Niels Louis-Hansen	Deputy Chairman	55.3yrs	DKK 938.00k	21.11% MX$ 105.4b
Marianne Wiinholt	Independent Director	2.4yrs	DKK 880.00k	0.00024% MX$ 1.2m
Jette Nygaard-Andersen	Independent Director	7.4yrs	DKK 600.00k	데이터 없음
Nikolaj Gundersen	Employees Representative Director	5.3yrs	DKK 450.00k	데이터 없음
Roland Pedersen	Employees Representative Director	5.3yrs	DKK 450.00k	0.00070% MX$ 3.5m
Annette Bruls	Independent Director	1.4yrs	DKK 497.00k	데이터 없음

5.3yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 0QBO N 의 이사회는 경험(평균 재직 기간 5.3 년)으로 간주됩니다.

Coloplast 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Less than half of directors are independent

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령